NCT07511504 2026-04-06
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
Clinical Trials
5 trialsNCT07226063 2025-11-10
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07122089 2025-08-14
IOSPHERE
Center Eugene Marquis
Phase 2 Not yet recruiting
NCT07012798 2025-06-10
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06111326 2023-11-01
BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Not yet recruiting